Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ZL-1310 |
| Trade Name | |
| Synonyms | ZL1310|ZL 1310|YL212|YL 212|YL-212|ADC SC-002 |
| Drug Descriptions |
ZL-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLL3 linked to a camptothecin derivative, which potentially inhibits tumor growth (ESMO Open, Volume 9, 102891). |
| DrugClasses | DLL3 Antibody 10 |
| CAS Registry Number | NA |
| NCIT ID | C203531 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Carboplatin + ZL-1310 | Atezolizumab Carboplatin ZL-1310 | 0 | 1 |
| Atezolizumab + ZL-1310 | Atezolizumab ZL-1310 | 0 | 1 |
| ZL-1310 | ZL-1310 | 0 | 2 |